Tominersen for huntington disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 15 Feb 2019: Trial registered, NCT03842969
  2. 23 Apr 2019: Trial started, NCT03842969

The trials

NCT02519036: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

State
Completed
Phase
Phase 1 and Phase 2
People
46 taking part
Started
6 Aug 2015
Primary completion
8 Nov 2017
Arms
ISIS 443139 10 mg, ISIS 443139 30 mg, ISIS 443139 60 mg, ISIS 443139 90 mg, ISIS 443139 120 mg
Results
Posted on the registry
  1. 6 Aug 2015: Trial started
  2. 10 Aug 2015: Trial registered
  3. 8 Nov 2017: Trial completed
  4. 31 May 2019: Trial results posted

NCT03342053: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

State
Completed
Phase
Phase 2
People
46 taking part
Started
2 Jan 2018
Primary completion
8 Oct 2019
Arms
RO7234292 Monthly, RO7234292 Bimonthly
Results
Posted on the registry
  1. 14 Nov 2017: Trial registered
  2. 2 Jan 2018: Trial started
  3. 8 Oct 2019: Trial completed
  4. 19 Jan 2021: Trial results posted

NCT03842969: An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

State
Completed
Phase
Phase 3
People
236 taking part
Started
23 Apr 2019
Primary completion
25 Mar 2022
Arms
RO7234292 (RG6042) Q8W, RO7234292 (RG6042) Q16W
Results
Posted on the registry
  1. 15 Feb 2019: Trial registered
  2. 23 Apr 2019: Trial started
  3. 30 Mar 2022: Trial completed
  4. 31 Aug 2023: Trial results posted

NCT05686551: GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

State
Under way
Phase
Phase 2
People
301 taking part
Started
3 Feb 2023
Primary completion
14 May 2026
Arms
Tominersen 60 milligrams (mg), Tominersen 100 mg
Results
None posted
  1. 17 Jan 2023: Trial registered
  2. 3 Feb 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as ISIS 443139 10 mg, ISIS 443139 120 mg, ISIS 443139 30 mg, ISIS 443139 60 mg, ISIS 443139 90 mg, RO7234292, RO7234292 (RG6042).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.